NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free STOK Stock Alerts $12.04 +0.39 (+3.35%) (As of 03:52 PM ET) Add Compare Share Share Today's Range$11.50▼$12.2050-Day Range$4.12▼$14.1752-Week Range$3.35▼$16.40Volume843,427 shsAverage Volume973,866 shsMarket Capitalization$557.45 millionP/E RatioN/ADividend YieldN/APrice Target$19.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Stoke Therapeutics alerts: Email Address Stoke Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside67.9% Upside$19.63 Price TargetShort InterestBearish15.01% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.57Based on 16 Articles This WeekInsider TradingSelling Shares$41.98 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.28) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.14 out of 5 starsMedical Sector129th out of 918 stocksPharmaceutical Preparations Industry43rd out of 423 stocks 4.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.01% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 39.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 3.1 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Stoke Therapeutics this week, compared to 4 articles on an average week.Search Interest23 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.MarketBeat Follows10 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,983,115.00 in company stock.Percentage Held by Insiders12.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.28) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Stoke Therapeutics Stock (NASDAQ:STOK)Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Read More STOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STOK Stock News HeadlinesApril 19, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in StockApril 2, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells $67,663.20 in StockApril 19, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereMarch 20, 2024 | insidertrades.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,349 Shares of StockApril 19, 2024 | yahoo.comStoke-on-Trent to host its first comedy festivalApril 19, 2024 | msn.comStoke City predicted starting XI vs Plymouth as Steven Schumacher weighs up old boys' claimsApril 19, 2024 | msn.comProtest outside Stoke-on-Trent Crown Court - here's whyApril 17, 2024 | finance.yahoo.comStoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerApril 19, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 17, 2024 | businesswire.comStoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerApril 17, 2024 | msn.comThe focus inside the Stoke City changing room ahead of Plymouth Argyle and 'biggest game of season'April 13, 2024 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Short Interest UpdateApril 13, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Needham & Company LLCApril 13, 2024 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Forecasted to Earn Q2 2024 Earnings of ($0.43) Per ShareApril 13, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for Stoke Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:STOK)April 12, 2024 | benzinga.comStoke Therapeutics Stock (NASDAQ:STOK), Analyst Ratings, Price Targets, PredictionsApril 12, 2024 | markets.businessinsider.comBuy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market PositioningApril 4, 2024 | businesswire.comStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | markets.businessinsider.comAssessing Stoke Therapeutics: Insights From 6 Financial AnalystsApril 4, 2024 | seekingalpha.comStoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The WatchlistApril 3, 2024 | markets.businessinsider.comStrong Buy Rating for Stoke Therapeutics’ STK-001 Backed by Positive KOL Feedback and Revolutionary Potential in Dravet Syndrome TreatmentApril 1, 2024 | msn.comStoke Stock (NASDAQ:STOK) Gains on Drug Update; Is There More Upside Left?March 27, 2024 | businesswire.comStoke Therapeutics Announces Pricing of Upsized $125 Million Public OfferingMarch 27, 2024 | markets.businessinsider.comStoke Therapeutics’ STK-001 Shows Promise: Buy Rating Affirmed Amid Positive Clinical and Financial OutlookMarch 27, 2024 | marketwatch.comStoke Therapeutics Shares Extend Gains to 52-Week High, Plans for $75M OfferingMarch 27, 2024 | bizjournals.comStoke Therapeutics plans $75M public offering on heels of Dravet trial resultsMarch 27, 2024 | msn.comWhat's Going On With Stoke Therapeutics Stock Tuesday?See More Headlines Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today4/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$19.63 High Stock Price Target$35.00 Low Stock Price Target$12.00 Potential Upside/Downside+68.5%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,700,000.00 Net MarginsN/A Pretax Margin-1,192.47% Return on Equity-56.86% Return on Assets-41.59% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.99 Sales & Book Value Annual Sales$8.78 million Price / Sales61.43 Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book3.26Miscellaneous Outstanding Shares46,300,000Free Float40,609,000Market Cap$539.40 million OptionableOptionable Beta0.77 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Edward M. Kaye M.D. (Age 75)Ph.D., CEO & Director Comp: $931.21kDr. Adrian R. Krainer Ph.D. (Age 65)Co-Founder & Independent Director Comp: $44kMr. Stephen J. Tulipano CPA (Age 65)MBA, Chief Financial Officer Comp: $619.09kDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Chief Medical Officer Comp: $688.83kMs. Isabel Aznarez Ph.D. (Age 51)Co-Founder & Group VP of Discovery Research Dr. Huw M. Nash Ph.D. (Age 57)COO & Chief Business Officer Comp: $429.67kMr. Eric RojasHead of Investor RelationsMr. Jonathan Allan J.D. (Age 34)Corporate Secretary & General Counsel Ms. Dawn Kalmar (Age 46)Chief Communications Officer Ms. Joan WoodChief Human Resources OfficerMore ExecutivesKey CompetitorsCogent BiosciencesNASDAQ:COGTCelcuityNASDAQ:CELCWave Life SciencesNASDAQ:WVEMersana TherapeuticsNASDAQ:MRSNDianthus TherapeuticsNASDAQ:DNTHView All CompetitorsInsiders & InstitutionsSkorpios TrustSold 3,600,000 sharesTotal: $41.76 M ($11.60/share)Jonathan AllanSold 5,126 sharesTotal: $67,663.20 ($13.20/share)Edward M Md KayeSold 11,150 sharesTotal: $68,015.00 ($6.10/share)Stephen J TulipanoSold 4,116 sharesTotal: $25,107.60 ($6.10/share)Jonathan AllanSold 2,349 sharesTotal: $14,328.90 ($6.10/share)View All Insider TransactionsView All Institutional Transactions STOK Stock Analysis - Frequently Asked Questions Should I buy or sell Stoke Therapeutics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STOK shares. View STOK analyst ratings or view top-rated stocks. What is Stoke Therapeutics' stock price target for 2024? 9 Wall Street research analysts have issued 12-month price targets for Stoke Therapeutics' stock. Their STOK share price targets range from $12.00 to $35.00. On average, they predict the company's share price to reach $19.63 in the next twelve months. This suggests a possible upside of 67.9% from the stock's current price. View analysts price targets for STOK or view top-rated stocks among Wall Street analysts. How have STOK shares performed in 2024? Stoke Therapeutics' stock was trading at $5.26 at the beginning of the year. Since then, STOK stock has increased by 122.2% and is now trading at $11.69. View the best growth stocks for 2024 here. Are investors shorting Stoke Therapeutics? Stoke Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,950,000 shares, an increase of 39.4% from the March 15th total of 3,550,000 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is currently 4.9 days. Approximately 15.0% of the company's shares are sold short. View Stoke Therapeutics' Short Interest. When is Stoke Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our STOK earnings forecast. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its quarterly earnings data on Monday, March, 25th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.02. The business earned $2.80 million during the quarter, compared to the consensus estimate of $3.70 million. What ETFs hold Stoke Therapeutics' stock? ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and WisdomTree BioRevolution Fund (WDNA).Global X Genomics & Biotechnology ETF (GNOM). What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA). When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STOK) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.